Aurobindo gets final USFDA nod for anti-fungal drug

Pharmaceuticals major expects to launch product in current quarter

Aurobindo Pharma Limited today announced it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Voriconazole tablets.

The company expects to launch the product in the current quarter.

The approved generic product is bioequivalent and therapeutically equivalent to the reference listed drug product VFEND Tablets of PF Prism C V, the company said.

Voriconazole tablets are used to fungal infections for patients of 12 years of age and above. The product has an estimated market size of $103 million for the twelve months ending November 2015, the company quoted IMS data.